What is INVO Fertility, Inc.'s earnings per share (EPS)?

INVO Fertility, Inc. (IVF) reported diluted earnings per share of -$214.64 for fiscal year 2025. This represents a 94.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INVO Fertility, Inc. (IVF) Financials

IVF

FY2025 annual

Revenue $6.8M +4.7% YoY

Net Income $23.3M +157.6% YoY

EPS (Diluted) -$214.64 +94.3% YoY

Free Cash Flow -$7.1M -123.5% YoY

Market Cap $2.4M as of Sep 15, 2026

Price / Sales 0.3x on $7.5M revenue, trailing 12 months to June 30, 2026

Price / Earnings 0.1x on $39.7M net income, trailing 12 months to June 30, 2026

Price / Book 0.1x on $16.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IVF SEC filings page.

INVO Fertility, Inc. (IVF) reported $6.8M in revenue for fiscal year 2025, up 4.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IVF FY2025 2026-08-30

99.6% gross margins coexist with persistent operating losses, making overhead and earnings quality the dominant business mechanics.

The most important disconnect is between reported profit and cash generation: FY2025 net income was $23.3M while operating cash flow was -$7.0M, after the same mismatch in FY2023 and FY2024. That pattern indicates earnings are being driven by items outside recurring cash operations, so net income alone does not describe the economic engine.

Gross margin was 99.6% in FY2025, yet operating loss was -$7.2M; this unusually wide gap means overhead absorbs almost all gross profit before interest. Revenue more than doubled from FY2023 to FY2024 while operating losses remained around $7M, indicating added volume has not materially changed fixed-cost absorption.

The FY2025 current ratio was 0.3x, while the reported liquidity comparison equaled 7.8 months of annual operating outflow; cash resources were not matched by near-term balance-sheet flexibility. Financing cash flow of $11.1M exceeded the year's operating cash outflow, while debt-to-equity was only 0.1x, so balance-sheet support was not dominated by long-term debt.

Financial Health Signals

Financial Health Score 33/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of INVO Fertility, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

INVO Fertility, Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 11/100.

Growth

INVO Fertility, Inc.'s revenue grew a modest 4.7% year-over-year to $6.8M. This slow but positive growth earns a score of 95/100.

Leverage

INVO Fertility, Inc. carries a low D/E ratio of 0.10, meaning only $0.10 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

INVO Fertility, Inc.'s current ratio of 0.27 is below the typical benchmark, resulting in a score of 1/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

INVO Fertility, Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.

Returns

INVO Fertility, Inc. generates a 322.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 9/100. This is up from 71.9% the prior year.

Altman Z-Score Distress

-7.51

INVO Fertility, Inc. scores -7.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.4M) relative to total liabilities ($13.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

INVO Fertility, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

$0.30used

For every $1 of reported earnings, INVO Fertility, Inc. used $0.30 of operating cash (-$7.0M OCF vs $23.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage At Risk

N/A

INVO Fertility, Inc. reported an operating loss of $7.2M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.2M

YoY+16.7%

QoQ+8.0%

5Y CAGR+59.8%

10Y CAGR+82.0%

INVO Fertility, Inc. generated $2.2M in revenue in Q2 2026. This represents an increase of 16.7% from the same quarter a year earlier. Against the prior quarter it is up 8.0%.

EBITDA

-$1.1M

YoY+59.4%

QoQ+21.0%

INVO Fertility, Inc.'s EBITDA was -$1.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 59.4% from the same quarter a year earlier. Against the prior quarter it is up 21.0%.

Net Income

$889K

YoY+124.6%

QoQ+116.0%

INVO Fertility, Inc. reported $889K in net income in Q2 2026. This represents an increase of 124.6% from the same quarter a year earlier. Against the prior quarter it is up 116.0%.

EPS (Diluted)

$0.35

INVO Fertility, Inc. earned $0.35 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$3.7M

YoY+579.7%

QoQ-23.9%

5Y CAGR-10.9%

10Y CAGR+27.7%

INVO Fertility, Inc. held $3.7M in cash against $513K in long-term debt as of Q2 2026, with $6.5M of liabilities due within a year.

Shares Outstanding

INVO Fertility, Inc. had 3M shares outstanding in Q2 2026.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

97.2%

YoY-2.6pp

QoQ-2.5pp

INVO Fertility, Inc.'s gross margin was 97.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.

Operating Margin

-59.3%

QoQ+19.7pp

INVO Fertility, Inc.'s operating margin was -59.3% in Q2 2026, reflecting core business profitability. Against the prior quarter it is up 19.7 percentage points. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

40.8%

INVO Fertility, Inc.'s net profit margin was 40.8% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

5.4%

QoQ+42.3pp

INVO Fertility, Inc.'s ROE was 5.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 42.3 percentage points.

Capital Allocation

None of these metrics is reported for Q2 2026.

IVF Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IVF quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$7.5M	$6.8M+4.7%	$6.5M+116.3%	$3.0M+267.4%	$822K-80.2%	$4.2M+301.1%	$1.0M-29.9%	$1.5M+199.4%	$494K+75.2%	$282K+454.3%	$51K+335.5%	$12K-29.5%	$17K-38.7%	$27K-52.0%	$56K-21.2%	$72K
Cost of Revenue	N/A	$31K+150.6%	$12K-99.4%	$2.0M+587.6%	$287K+127.1%	$126K+59.8%	$79K-40.9%	$134K+47.9%	$90K+73.9%	$52K+244.2%	$15K+93.3%	$8K+1.7%	$8K-27.4%	$11K-49.3%	$21K+16.6%	$18K
Gross Profit	N/A	$6.8M+4.5%	$6.5M+522.3%	$1.0M+113.5%	$491K-87.8%	$4.0M+323.3%	$949K-29.2%	$1.3M+231.8%	$404K+75.5%	$230K+542.9%	$36K+823.1%	$4K-56.4%	$9K-46.0%	$16K-53.6%	$35K-33.8%	$54K
R&D Expenses	N/A	N/A	$5K-97.1%	$166K-69.5%	$544K+151.4%	$216K-45.7%	$398K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$8.0M	$7.7M-4.6%	$8.1M+7.7%	$7.5M-25.0%	$10.0M+10.7%	$9.0M+48.6%	$6.1M+93.9%	$3.1M+3.0%	$3.0M+249.0%	$871K	N/A	$599K	N/A	N/A	$588K	N/A
Operating Income	-$5.9M	-$7.2M-9.2%	-$6.6M+2.1%	-$6.8M+36.3%	-$10.6M-103.7%	-$5.2M+5.4%	-$5.5M-208.4%	-$1.8M+32.1%	-$2.6M-311.3%	-$640K	N/A	-$595K	N/A	-$605K-9.6%	-$552K	N/A
EBITDA	N/A	-$6.6M-14.9%	-$5.7M+13.1%	-$6.6M+37.8%	-$10.5M-103.3%	-$5.2M+5.7%	-$5.5M-209.6%	-$1.8M+32.4%	-$2.6M-312.3%	-$638K	N/A	-$589K	N/A	-$594K-9.8%	-$541K	N/A
Interest Expense	$1.5M	$1.3M+23.3%	$1.1M+14.1%	$926K+1457.6%	$59K-95.3%	$1.3M-55.4%	$2.8M+631.7%	$388K-12.3%	$442K+2017.7%	$21K+50.8%	$14K-56.8%	$32K-38.3%	$52K0.0%	$52K-44.1%	$93K-40.3%	$156K
Income Tax	N/A	-$150K-207.3%	$140K+404.6%	$28K+867.5%	$3K-39.7%	$5K+13133.3%	$36-91.7%	$433	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$39.7M	$23.3M+157.6%	$9.1M+12.7%	$8.0M+173.8%	-$10.9M-63.7%	-$6.7M+20.3%	-$8.3M-285.1%	-$2.2M+29.5%	-$3.1M-338.1%	-$702K	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Basic)	N/A	-$214.64-5574.3%	-$3.78+94.4%	-$67.37-274.9%	-$17.97-2752.4%	-$0.63+58.6%	-$1.52-237.8%	-$0.45-2150.0%	-$0.02	$0.00+100.0%	-$0.02+50.0%	-$0.04-100.0%	-$0.02-100.0%	-$0.010.0%	-$0.010.0%	-$0.01
EPS (Diluted)	—	-$214.64+94.3%	-$3782.65	-$67.37-274.9%	-$17.97	-$0.63	-$1.52	-$0.45	-$0.02	$0.00+100.0%	-$0.02+50.0%	-$0.04-100.0%	-$0.02-100.0%	-$0.010.0%	-$0.010.0%	-$0.01
Diluted Shares (Avg)	N/A	117,083+4557.2%	2,514	119,264-80.3%	606,130	11M	5M	5M	147M+4.3%	141M+1.5%	139M+8.3%	129M+14.1%	113M+5.2%	107M+20.2%	89M+13.2%	79M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$2.2M+16.7%	$2.0M+23.1%	$1.6M-6.1%	$1.8M+22.6%	$1.9M+1.5%	$1.6M+3.9%	$1.7M+22.0%	$1.4M+47.0%
Cost of Revenue	$60K+1863.7%	$5K+29.3%	N/A	N/A	$3K-99.6%	$4K-99.5%	-$2.7M-346.6%	$988K+70.1%
Gross Profit	$2.1M+13.7%	$2.0M+23.1%	N/A	N/A	$1.9M+90.8%	$1.6M+128.7%	$4.4M+1371.2%	$445K+12.9%
R&D Expenses	N/A	N/A	N/A	N/A	N/A	$266K+5343.9%	N/A	N/A
SG&A Expenses	$1.9M-13.1%	$2.2M+39.7%	$1.8M-26.4%	$2.1M+40.5%	$2.2M-17.2%	$1.6M+8.1%	$2.5M+32.7%	$1.5M+20.5%
Operating Income	-$1.3M+56.9%	-$1.6M-32.6%	-$1.4M+28.2%	-$1.6M-25.8%	-$3.0M-61.4%	-$1.2M+20.5%	-$2.0M-30.4%	-$1.3M-46.7%
EBITDA	-$1.1M+59.4%	-$1.4M-50.1%	-$1.3M+26.4%	-$1.5M-40.1%	-$2.8M-73.8%	-$965K+24.7%	-$1.7M-26.9%	-$1.1M-23.6%
Interest Expense	$177K-59.8%	$180K+157.9%	$1.0M+72.8%	$146K-46.7%	$441K+19.2%	-$311K-71.7%	$594K+226.5%	$274K-22.3%
Income Tax	$56K	$0	N/A	N/A	N/A	$0-100.0%	N/A	$29K+1451.4%
Net Income	$889K+124.6%	-$5.5M+68.2%	$47.7M+228.7%	-$3.4M-108.2%	-$3.6M-61.2%	-$17.4M-990.1%	$14.5M+3.2%	-$1.6M-30.6%
EPS (Basic)	$0.42+100.1%	-$3.38+99.9%	$472.78+1756.0%	-$39.40-160.8%	-$364.23-1526.8%	-$3473.93-45912.3%	-$28.55-4631.7%	-$15.11-2058.6%
EPS (Diluted)	$0.35	-$3.38	$472.78+1756.0%	-$39.40	-$364.23	-$3473.93	-$28.55	-$15.11
Diluted Shares (Avg)	3M	2M	N/A	3M	9,936	5,010	N/A	107,949

IVF Balance Sheet

IVF quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$20.2M-56.1%	$46.1M+149.0%	$18.5M+398.8%	$3.7M-62.9%	$10.0M-8.7%	$10.9M+509.7%	$1.8M+131.0%	$777K+191.8%	$266K-6.9%	$286K-50.6%	$580K+436.6%	$108K-11.8%	$123K-2.2%	$125K-2.0%	$128K
Current Assets	$2.8M+119.8%	$1.3M-0.3%	$1.3M+102.8%	$621K-90.2%	$6.3M-40.2%	$10.5M+583.1%	$1.5M+111.1%	$731K+211.9%	$234K-6.8%	$251K-55.0%	$559K+586.4%	$81K-4.6%	$85K+11.5%	$77K+13.2%	$68K
Cash & Equivalents	$2.1M+235.4%	$620K+166.5%	$232K+157.9%	$90K-98.4%	$5.7M-43.7%	$10.1M+715.3%	$1.2M+483.6%	$212K+724.0%	$26K-83.1%	$152K-69.0%	$492K+2541.5%	$19K+3.3%	$18K+150.6%	$7K+1685.1%	$403
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$225K+2.5%	$220K-16.9%	$265K+0.3%	$264K-8.4%	$288K+8.4%	$265K+161.7%	$101K+133.0%	$44K-26.1%	$59K-30.9%	$85K+30.3%	$65K+4.7%	$62K-4.8%	$66K+21.7%	$54K-9.5%	$60K
Accounts Receivable	$217K+92.1%	$113K-19.5%	$141K+82.2%	$77K+52.9%	$50K+132.6%	$22K+187.1%	$8K-96.7%	$226K+160.6%	$87K+3003.0%	$3K+107.6%	$1K+319.3%	$321-81.8%	$2K-85.8%	$12K+123.4%	$6K
Long-Term Investments	$2.5M	$0	$0	$0	$0-100.0%	$98K	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$5.9M0.0%	$5.9M0.0%	$5.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.0M-50.1%	$26.0M+47.8%	$17.6M+275.8%	$4.7M+74.7%	$2.7M-48.4%	$5.2M-5.5%	$5.5M+57.3%	$3.5M-33.4%	$5.3M+7.2%	$4.9M+13.1%	$4.3M-2.9%	$4.5M+13.5%	$3.9M+12.6%	$3.5M+14.6%	$3.1M
Current Liabilities	$10.3M-42.2%	$17.9M+123.3%	$8.0M+139.8%	$3.3M+184.2%	$1.2M-48.7%	$2.3M+52.4%	$1.5M-57.1%	$3.5M-31.7%	$5.1M+7.4%	$4.8M+10.0%	$4.3M-2.9%	$4.5M+13.5%	$3.9M+12.6%	$3.5M+14.6%	$3.1M
Non-Current Liabilities	$2.7M-67.4%	$8.2M-15.0%	$9.6M+612.2%	$1.3M-10.6%	$1.5M-48.3%	$2.9M-27.2%	$4.0M	$0-100.0%	$132K0.0%	$132K	$0	$0	$0	$0	$0
Long-Term Debt	$745K-34.0%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.2M-42.6%	$12.6M+1309.5%	$893K+191.3%	-$978K-113.4%	$7.3M+27.3%	$5.7M+254.7%	-$3.7M-36.3%	-$2.7M+45.4%	-$5.0M-8.1%	-$4.6M-22.9%	-$3.8M+13.8%	-$4.4M-14.3%	-$3.8M-13.1%	-$3.4M-15.3%	-$2.9M
Retained Earnings	-$91.4M-35.7%	-$67.3M-16.4%	-$57.8M-16.1%	-$49.8M-28.0%	-$38.9M-20.6%	-$32.2M-34.9%	-$23.9M-10.0%	-$21.7M-16.5%	-$18.6M-3.9%	-$17.9M-13.4%	-$15.8M-45.7%	-$10.9M-19.0%	-$9.1M-9.1%	-$8.4M-8.7%	-$7.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$25.8M+33.7%	$24.7M-22.3%	$20.2M-56.1%	$18.8M+10.7%	$19.3M+8.8%	$31.7M+83.1%	$46.1M+149.0%	$17.0M-0.1%
Current Assets	$4.6M+228.9%	$5.7M+265.4%	$2.8M+119.8%	$1.1M-41.9%	$1.4M-41.6%	$1.6M-9.0%	$1.3M-0.3%	$2.0M+9.2%
Cash & Equivalents	$3.7M+579.7%	$4.9M+483.6%	$2.1M+235.4%	$356K-28.8%	$549K-39.0%	$840K+76.9%	$620K+166.5%	$500K-52.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$251K+18.2%	$225K+3.7%	$225K+2.5%	$192K-20.6%	$213K-15.0%	$216K-18.8%	$220K-16.9%	$242K-5.0%
Accounts Receivable	$258K+6.4%	$248K+43.1%	$217K+92.1%	$274K+6.7%	$242K-5.8%	$174K-1.9%	$113K-19.5%	$257K+120.1%
Long-Term Investments	$2.5M0.0%	$2.5M	$2.5M	$2.5M	$2.5M	$0	$0	$0
Goodwill	$9.3M+57.4%	$6.5M-26.7%	$5.9M0.0%	$5.9M0.0%	$5.9M0.0%	$8.9M+51.2%	$5.9M0.0%	$5.9M-28.5%
Total Liabilities	$9.3M-64.7%	$9.6M-83.7%	$13.0M-50.1%	$13.0M-23.6%	$26.5M+61.5%	$58.9M+240.1%	$26.0M+47.8%	$17.0M+2.3%
Current Liabilities	$6.5M-46.3%	$6.4M-66.0%	$10.3M-42.2%	$9.1M+5.4%	$12.1M+52.6%	$18.7M+112.7%	$17.9M+123.3%	$8.7M+85.4%
Non-Current Liabilities	$2.8M-80.3%	$3.3M-91.9%	$2.7M-67.4%	$3.9M-53.6%	$14.3M+69.9%	$40.2M+371.5%	$8.2M-15.0%	$8.4M-30.1%
Long-Term Debt	$513K-50.7%	$660K	$745K-34.0%	$952K	$1.0M	N/A	$1.1M	N/A
Total Equity	$16.5M+330.5%	$15.0M+155.2%	$7.2M-42.6%	$5.8M+25051.5%	-$7.2M-624.6%	-$27.2M-267975.4%	$12.6M+1309.5%	-$23K-106.3%
Retained Earnings	-$96.0M-6.5%	-$96.9M-14.2%	-$91.4M-35.7%	-$92.2M-45.1%	-$90.2M-45.7%	-$84.9M-42.8%	-$67.3M-16.4%	-$63.5M-13.8%

IVF Cash Flow Statement

IVF quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$4.8M	-$7.0M-135.8%	-$3.0M+37.4%	-$4.8M+28.0%	-$6.6M-9.5%	-$6.0M-26.3%	-$4.8M-448.4%	$1.4M+309.9%	-$653K-260.2%	-$181K+44.0%	-$324K-113.6%	-$152K-681.5%	-$19K+67.6%	-$60K-38.7%	-$43K+63.3%	-$118K
Depreciation & Amortization	N/A	$677K-26.3%	$920K+357.8%	$201K+159.9%	$77K+178.5%	$28K+132.9%	$12K+10.5%	$11K+107.9%	$5K+84.7%	$3K+49.6%	$2K-66.7%	$6K-46.5%	$11K-8.5%	$12K0.0%	$12K-46.1%	$21K
Stock-Based Compensation	N/A	$163K	N/A	N/A	$1.6M+4.7%	$1.5M+35.3%	$1.1M+1535.0%	$70K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	$43K-76.4%	$184K-58.7%	$445K+4023.5%	$11K-97.4%	$416K+743.9%	$49K-24.0%	$65K+234.2%	$19K	$0-100.0%	$16K	$0	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	-$7.1M-123.5%	-$3.2M+39.3%	-$5.2M+21.4%	-$6.6M-2.6%	-$6.4M-33.6%	-$4.8M-469.5%	$1.3M+294.2%	-$672K-270.9%	-$181K+46.6%	-$340K-124.0%	-$152K	N/A	N/A	N/A	N/A
Investing Cash Flow	-$2.9M	-$2.7M-854.5%	$364K+114.6%	-$2.5M-2971.9%	-$81K+96.2%	-$2.2M-1050.0%	-$187K-63.2%	-$115K-491.3%	-$19K	$0+100.0%	-$16K	$0	N/A	N/A	N/A	N/A
Financing Cash Flow	$10.9M	$11.1M+255.7%	$3.1M-57.8%	$7.4M+578.3%	$1.1M-71.1%	$3.8M-72.7%	$13.8M+6123.4%	-$229K-126.7%	$859K+1472.3%	$55K	$0-100.0%	$625K+3025.0%	$20K-71.7%	$71K+41.5%	$50K-52.7%	$106K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.1M+35.9%	-$1.9M+45.9%	$25K+104.1%	-$1.8M-177.2%	-$1.7M-18.0%	-$3.5M-1260.8%	-$617K+13.6%	-$641K+48.6%
Depreciation & Amortization	$146K-14.2%	$143K-39.1%	$136K-41.1%	$137K-40.7%	$170K-26.3%	$234K+3.3%	$232K+63.7%	$230K+1024.1%
Capital Expenditures	N/A	N/A	$12K-85.0%	$8K	$9K-83.9%	$15K-70.5%	$79K+5.2%	$0-100.0%
Free Cash Flow	N/A	N/A	$13K+101.9%	-$1.8M-178.5%	-$1.7M-14.3%	-$3.6M-1047.5%	-$696K+11.9%	-$641K+52.7%
Investing Cash Flow	-$2K+85.7%	-$210K-1333.4%	-$2.7M-788.7%	-$8K	-$15K-201.0%	-$15K+39.2%	$393K+1080.9%	$0+100.0%
Financing Cash Flow	-$68K-104.7%	$5.0M+35.4%	$4.4M+791.4%	$1.6M+839.0%	$1.4M-25.2%	$3.7M+593.9%	$494K+449.1%	$169K-96.2%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

IVF Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IVF quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	99.6%-0.3pp	99.8%+65.1pp	34.7%-25.0pp	59.7%-36.8pp	96.5%+5.1pp	91.4%+0.9pp	90.6%+8.8pp	81.7%+0.1pp	81.6%+11.2pp	70.3%+37.2pp	33.2%-20.5pp	53.7%-7.2pp	60.9%-2.1pp	63.0%-12.0pp	75.0%
Operating Margin	-105.8%	-101.5%	-224.0%	-1292.5%	-125.4%	-531.7%	-120.8%	-532.8%	-227.0%	N/A	-5090.9%	N/A	-2236.4%	-979.6%	N/A
Net Margin	340.9%	138.6%	266.0%	-1324.8%	-160.0%	-804.7%	-146.4%	-622.2%	-248.9%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	322.8%+250.9pp	71.9%-828.0pp	899.9%	N/A	-91.0%+54.3pp	-145.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	115.3%+95.7pp	19.7%-23.8pp	43.4%+337.0pp	-293.6%-227.0pp	-66.6%+9.7pp	-76.3%+44.5pp	-120.7%+275.0pp	-395.7%-132.2pp	-263.6%	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.27+0.2x	0.07-0.1x	0.160.0x	0.19-5.2x	5.37+0.8x	4.61+3.6x	1.03+0.8x	0.21+0.2x	0.050.0x	0.05-0.1x	0.13+0.1x	0.020.0x	0.020.0x	0.020.0x	0.02
Debt-to-Equity	0.100.0x	0.09-19.6x	19.73	N/A	0.37-0.5x	0.91	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.34+0.2x	0.140.0x	0.16-0.1x	0.22-0.2x	0.42+0.3x	0.09-0.7x	0.82+0.2x	0.64-0.4x	1.06+0.9x	0.18+0.2x	0.02-0.1x	0.15-0.1x	0.22-0.2x	0.45-0.1x	0.56
FCF Margin	-103.2%	-48.4%	-172.2%	-804.4%	-154.9%	-465.1%	88.2%	-136.0%	-64.3%	-667.2%	-1297.1%	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	97.2%-2.6pp	99.7%0.0pp	N/A	N/A	99.8%+46.8pp	99.8%+54.4pp	260.1%	31.0%-9.4pp
Operating Margin	-59.3%	-79.0%-5.7pp	-89.2%	-93.1%-2.3pp	-160.4%	-73.3%+22.4pp	-116.6%	-90.7%+0.2pp
Net Margin	40.8%	-274.9%	3015.3%	-193.3%	-194.2%	-1063.0%	861.6%	-113.8%
Return on Equity	5.4%	-36.9%	660.9%+545.4pp	-58.4%	N/A	N/A	115.4%-1461.0pp	N/A
Return on Assets	3.4%+22.2pp	-22.5%+32.4pp	236.1%+204.6pp	-18.0%-8.4pp	-18.7%-6.1pp	-54.8%-45.6pp	31.5%-44.5pp	-9.6%-2.2pp
Current Ratio	0.71+0.6x	0.90+0.8x	0.27+0.2x	0.12-0.1x	0.12-0.2x	0.08-0.1x	0.07-0.1x	0.23-0.2x
Debt-to-Equity	0.03	0.04	0.100.0x	0.16	N/A	N/A	0.09-19.6x	N/A
Asset Turnover	0.080.0x	0.080.0x	0.080.0x	0.090.0x	0.100.0x	0.050.0x	0.040.0x	0.080.0x
FCF Margin	N/A	N/A	0.9%+42.1pp	-101.6%	-92.6%-10.4pp	-217.5%	-41.3%+15.9pp	-44.7%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.27), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
INVO Fertility, Inc. IVF	FY2025	$6.8M	$23.3M	N/A	$2.4M	33/100
VENUS CONCEPT INC VERO	FY2024	$64.8M	-$47.0M	-72.5%	$2.1M	—
Tivic Health Systems, Inc. TIVC	FY2025	N/A	-$8.9M	N/A	$4.0M	—
NanoVibronix, Inc. NAOV	FY2025	$2.6M	-$18.2M	N/A	$4.4M	27/100
Nuwellis, Inc. NUWE	FY2025	$8.3M	-$17.5M	N/A	$2.5M	45/100

Where INVO Fertility, Inc. Ranks

Frequently Asked Questions

What is INVO Fertility, Inc.'s annual revenue?

INVO Fertility, Inc. (IVF) reported $6.8M in total revenue for fiscal year 2025. This represents a 4.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is INVO Fertility, Inc.'s revenue growing?

INVO Fertility, Inc. (IVF) revenue grew by 4.7% year-over-year, from $6.5M to $6.8M in fiscal year 2025.

Is INVO Fertility, Inc. profitable?

Yes, INVO Fertility, Inc. (IVF) reported a net income of $23.3M in fiscal year 2025.

What is INVO Fertility, Inc.'s EBITDA?

INVO Fertility, Inc. (IVF) had EBITDA of -$6.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does INVO Fertility, Inc. have?

As of fiscal year 2025, INVO Fertility, Inc. (IVF) had $2.1M in cash and equivalents against $745K in long-term debt.

What is INVO Fertility, Inc.'s gross margin?

INVO Fertility, Inc. (IVF) had a gross margin of 99.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is INVO Fertility, Inc.'s return on equity (ROE)?

INVO Fertility, Inc. (IVF) has a return on equity of 322.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is INVO Fertility, Inc.'s free cash flow?

INVO Fertility, Inc. (IVF) recorded an outflow of $7.1M in free cash flow during fiscal year 2025. This represents a -123.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is INVO Fertility, Inc.'s operating cash flow?

INVO Fertility, Inc. (IVF) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are INVO Fertility, Inc.'s total assets?

INVO Fertility, Inc. (IVF) had $20.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are INVO Fertility, Inc.'s capital expenditures?

INVO Fertility, Inc. (IVF) invested $43K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

What is INVO Fertility, Inc.'s current ratio?

INVO Fertility, Inc. (IVF) had a current ratio of 0.27 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is INVO Fertility, Inc.'s debt-to-equity ratio?

INVO Fertility, Inc. (IVF) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is INVO Fertility, Inc.'s return on assets (ROA)?

INVO Fertility, Inc. (IVF) had a return on assets of 115.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is INVO Fertility, Inc.'s P/E ratio?

INVO Fertility, Inc. (IVF) trades at 0.1x earnings, its market capitalization divided by net income of $39.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.4M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is INVO Fertility, Inc.'s price-to-sales ratio?

INVO Fertility, Inc. (IVF) trades at 0.3x sales, its market capitalization divided by revenue of $7.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.4M as of Sep 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does INVO Fertility, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, INVO Fertility, Inc. (IVF) held $4.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is INVO Fertility, Inc.'s Altman Z-Score?

INVO Fertility, Inc. (IVF) has an Altman Z-Score of -7.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is INVO Fertility, Inc.'s Piotroski F-Score?

INVO Fertility, Inc. (IVF) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are INVO Fertility, Inc.'s earnings high quality?

For every $1 of reported earnings, INVO Fertility, Inc. (IVF) used $0.30 of operating cash (-$7.0M OCF vs $23.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can INVO Fertility, Inc. cover its interest payments?

INVO Fertility, Inc. (IVF) reported an operating loss of $7.2M against $1.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is INVO Fertility, Inc.?

INVO Fertility, Inc. (IVF) scores 33 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.